Skip to main content

Fiscal Wizard · Single-issue tearsheet

QDEL / Jun 20, 2026 Run #7204

QDEL

QuidelOrtho Corporation

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Composite verdict

F 22.2 / 100
Bearish setup · Reversal 6 drivers · 3 gates blocking
  • Engulfing
  • Parabolic SAR Flip
  • Stochastic Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 72nd of 141 in Medical Devices

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 32Mean-reversion Bearish 31

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety +91%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

36.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Free Cash Flow Yield 0
Margin of Safety 100
Revenue Growth (YoY) 0
Forward P/E 80
Cash Conversion Cycle 0

Technicals Bearish

8.2 / 100

Bearish setup leads (Engulfing, Parabolic SAR Flip, Stochastic Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Engulfing 12
Parabolic SAR Flip 15
Stochastic Cross 22

Risk Gates

3 blocking 9 caution

3 guards active, 23 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for QDEL.